Takeda's FY2025 results show revenue growth amidst lowered profit

Takeda Pharmaceutical (TSE:4502) reported its FY2025 consolidated financial results, showcasing revenue growth but a decline in profits amid strategic investments and a changing pharmaceutical landscape. Revenue increased by 7.5% to JPY 4,581.6 billion, driven by key business areas like Gastroenterology, Rare Diseases, and Plasma-Derived Therapies, alongside favorable foreign exchange rates. However, net profit for the year fell 25% to JPY 108.1 billion, influenced by higher tax expenses and strategic investment decisions.